ERBB2 and triple-negative breast carcinoma: Similar to the increased benefit of platinum therapy in metastatic triple-negative breast cancer in BRCA 1/2 positive patients [19] and a poorer prognosis in docetaxel and trastuzumab +/- pertuzumab therapy in HER2 amplified metastatic breast cancer in patients with a PIK3CA mutation [20], NGS can provide a foundation on which to maximize clinical benefit of highly targeted therapies based on tumor mutational signatures.